Therefore, this study aimed to compare the cost-effectiveness of palbociclib and ribociclib with their approved FDA combinations in stage IV HR+/HER-2 negative breast cancer females in the state of Qatar, which can also serve as a guide for countries with similar healthcare and economic profiles to Qatar. Here, ERBB2 is linked to breast carcinoma.